Immune Evaluation for Postoperative Sepsis-AKI

Development of an Immune Evaluation System for Postoperative Sepsis-Associated Acute Kidney Injury

This prospective, multicenter, observational cohort study plans to enroll over 800 patients with postoperative sepsis from the ICUs of two tertiary hospitals in Beijing. The study will establish a clinical database and biobank for sepsis-associated acute kidney injury (SA-AKI), characterize clinical and immune phenotypes, and develop an immune evaluation system. Using multi-omics and single-cell sequencing, we aim to identify novel immune biomarker panels and explore early warning and risk-stratification strategies based on immune profiling.

Inclusion Criteria:

• Age ≥ 18 years;
• Admitted to the ICU due to clinical necessity after surgical procedure;
• Expected ICU length of stay > 48 hours;
• Sepsis diagnosed according to the Sepsis-3.0 criteria;
• Patient or legally authorized representative is able to understand the study protocol, willing to participate, and provides written informed consent.

Exclusion Criteria:

• Patients with active malignancy undergoing chemotherapy, radiotherapy, or targeted therapy; patients with immune diseases receiving immunosuppressive or targeted agents; or patients who developed neutropenia/lymphopenia prior to sepsis onset due to hematologic disorders or receipt of immunosuppressive therapy;
• Patients in a moribund state with no resuscitative intent; patients with do-not-resuscitate (DNR) or withdrawal-of-care orders;
• Patients who do not meet the inclusion criteria.